After 10 years developing efti and Marc's clear strategy of BP being our customers
After good/ great data which has been the mantra of many 'to let the data do the talking'. P2 data sets in.
Where to from here?
Multiple P3 trials not on the agenda - also Marc
So we do one P3 - not AIPAC as NSCLC/HNC has more commercial potential - Marc
NSCLC/ HNC - combo with Keytruda.
On that basis we would have only one potential customer.
Could be that Merck is playing us and has perfect macro conditions to do.....nothing. Supply agreement maybe?
Competitive tension?
Business success = USP (unique selling proposition) and profitable exploitation of USP over X time.
We have efti - it works as a unique adjuvant in combo with PD-1 and chemo and possibly others.
Lag-3 is now proven as the next ICI pillar. BMS have FDA and soon EMA approval for Relatlimab in combo with their PD-1 (Opdivo).
After 30 years since Freddie discovered efti, I would not agree that monetisation of efti is a 'knee jerk' reaction to current macro conditions.
- Forums
- ASX - By Stock
- IMM
- Overnight Market report
Overnight Market report, page-564
-
- There are more pages in this discussion • 2,273 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $515.6M |
Open | High | Low | Value | Volume |
34.0¢ | 36.0¢ | 34.0¢ | $1.270M | 3.611M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 286261 | 35.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.0¢ | 253490 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 286261 | 0.355 |
1 | 18652 | 0.350 |
2 | 21902 | 0.345 |
2 | 17500 | 0.340 |
5 | 110996 | 0.330 |
Price($) | Vol. | No. |
---|---|---|
0.360 | 253490 | 7 |
0.365 | 82652 | 5 |
0.370 | 128958 | 4 |
0.375 | 95000 | 3 |
0.380 | 201873 | 5 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |